Robert F. Kennedy Jr. and a group of personal injury lawyers have long accused Merck & Co. of “disease mongering” to boost ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the successful completion of the ...
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today the publication of work describing the large-scale synthesis of enlicitide decanoate, the company’s ...
Pipeline momentum: Merck’s CAPVAXIVE and V116 pneumococcal vaccines showed strong Phase 3 results, moving toward potential market leadership. Policy turbulence: Recent U.S. vaccine policy changes and ...
Terns is now a wholly-owned subsidiary of Merck and its stock will no longer be listed or traded on the Nasdaq Global Select ...
Merck narrowed its 2026 sales guidance and hiked its adjusted profit outlook.
Merck (NYSE:MRK | MRK Price Prediction) delivered its fourth consecutive earnings beat, but shares slipped on the earnings ...
Merck's BioReliance® testing services support Genetix' gene therapy commercialization.
Feb 23 (Reuters) - Merck said on Monday it would create a separate division for its cancer business, anchored by its top-selling drug Keytruda, as the U.S. drugmaker braces for the upcoming patent ...
MSD (Merck) will acquire Terns Pharmaceuticals for approximately USD 6.7 billion, adding investigational leukemia therapy ...
Merck is tapping a number of baseball ambassadors to support its cardiovascular awareness push, including former World Series ...
Q1 earnings beat lifts shares; 2026 guidance narrows as Keytruda grows, Gardasil declines and R&D jumps on deals.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results